Lulizumab pegol
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | glycoprotein CD28 |
| Clinical data | |
| Other names | BMS-931699 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C552H859N149O164S4 |
| Molar mass | 12335.06 g·mol−1 |
Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody developed by Bristol-Myers Squibb for the treatment of autoimmune diseases[2] such as cutaneous lupus erythematosus.[3]
References
- ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol]" (PDF). American Medical Association.
- ^ Kuhn A, Landmann A, Wenzel J (July 2016). "Advances in the treatment of cutaneous lupus erythematosus". Lupus. 25 (8): 830–837. doi:10.1177/0961203316641771. PMID 27252259.